Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia

Introduction: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. Methods: This cross-sectional study included 1592 randomly se...

ver descrição completa

Detalhes bibliográficos
Principais autores: Salma Al Bahrani, Ali Albarrak, Othman Ali Alghamdi, Mesfer Abdullah Alghamdi, Fatimah H. Hakami, Asmaa K. Al Abaadi, Sausan A. Alkhrashi, Mansour Y. Alghamdi, Meshael M. Almershad, Mansour Moklif Alenazi, Mohamed Hany El Gezery, Arulanantham Zechariah Jebakumar, Jaffar A. Al-Tawfiq
Formato: Artigo
Idioma:English
Publicado em: Elsevier 2021-09-01
coleção:International Journal of Infectious Diseases
Assuntos:
ChAdOx1-S
COVID-19 vaccine
SARS-CoV-2
Oxford-AstraZeneca vaccine
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S1201971221006081

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221006081

Registros relacionados